dna
vaccin
great
interest
sinc
discoveri
due
abil
elicit
humor
cellular
immun
respons
dna
vaccin
consist
dna
plasmid
contain
transgen
encod
sequenc
target
protein
pathogen
control
eukaryot
promot
revolutionari
technolog
proven
effect
anim
model
four
dna
vaccin
product
recent
approv
veterinari
use
although
dna
vaccin
bacteri
infect
test
result
encourag
versatil
safeti
simplic
wider
rang
organ
target
vaccin
show
potenti
advantag
public
health
articl
describ
mechan
action
dna
vaccin
potenti
use
target
bacteri
infect
addit
provid
updat
summari
method
use
enhanc
immunogen
codon
optim
adjuv
deliveri
techniqu
includ
electropor
use
nanoparticl
keyword
bacteri
vaccin
cellular
humor
immun
respons
dna
vaccin
molecular
adjuv
time
chang
sinc
edward
jenner
immun
jame
phipp
smallpox
creat
year
later
becam
known
vaccin
first
liveattenu
kill
vaccin
era
dna
vaccin
earli
molecular
biolog
microbiolog
aid
medic
research
develop
vaccin
infecti
diseas
cancer
allergi
autoimmun
diseas
induc
rapid
robust
immun
respons
creat
immun
toler
time
jenner
first
vaccin
present
day
licens
vaccin
usa
vaccin
come
mani
form
kill
microorgan
liveattenu
microorgan
subunit
conjug
vaccin
toxoid
although
us
fdaapprov
dna
vaccin
use
human
newest
vaccin
platform
current
develop
alreadi
success
veterinari
medicin
dna
vaccin
genet
vaccin
involv
intramuscular
subcutan
inject
dna
plasmid
contain
transgen
encod
sequenc
target
protein
pathogen
control
eukaryot
promot
first
studi
suggest
inject
dna
plasmid
vivo
could
lead
product
plasmidencod
protein
conduct
ito
show
inject
nake
papillomaviru
dna
could
induc
tumor
rabbit
addit
atanasiu
et
al
achiev
compar
result
inocul
hamster
polyomaviru
group
report
util
similar
techniqu
could
induc
rat
cardiac
myocyt
express
recombin
howev
first
evid
literatur
immunolog
use
dna
provid
tang
et
al
studi
found
inject
human
growth
hormon
hgh
dna
skin
mous
use
gene
gun
abl
rais
hghand
human
haat
specif
antibodi
suggest
dna
may
suitabl
rout
induct
immun
respons
pathogen
infect
year
annual
vaccin
meet
cold
spring
harbor
laboratori
ny
usa
liu
et
al
robinson
et
al
weiner
et
al
gave
rise
new
era
vaccin
describ
use
dna
immun
influenza
subsequ
mani
other
describ
similar
result
follow
dna
immun
rabi
viru
bovin
herpesviru
hepat
b
surfac
antigen
articl
provid
detail
review
use
dna
vaccin
potenti
use
target
bacteri
infect
also
summar
signific
effort
made
improv
potenc
order
achiev
better
outcom
futur
clinic
trial
purpos
articl
provid
updat
new
achiev
field
immunolog
molecular
biolog
tailor
effect
protect
therapeut
immun
respons
use
vaccin
analyz
futur
prospect
technolog
dna
vaccin
plasmid
divid
two
main
structur
plasmid
backbon
transcript
unit
figur
transcript
unit
contain
promot
insert
gene
encod
antigen
interest
follow
transcript
terminationpolyadenyl
sequenc
plasmid
backbon
contain
origin
replic
amplif
plasmid
bacteria
well
antibiot
resist
gene
confer
resist
kanamycin
exampl
enabl
select
growth
plasmid
bacteria
commerci
avail
vector
approv
clinic
use
contain
escherichia
coli
origin
replic
puc
replic
plasmid
bacteria
produc
mani
copi
plasmid
rel
short
period
time
addit
mammalian
origin
replic
may
ad
replic
mammalian
cell
help
prolong
persist
express
transgen
topic
intens
investig
despit
rel
weak
activ
promot
compar
viral
counterpart
research
use
nonvir
promot
mhc
class
ii
promot
current
investig
possibl
altern
chimer
synthet
promot
also
consid
field
transgeneth
possibl
encod
multipl
protein
singl
construct
import
advantag
dna
vaccin
platform
one
antigen
ad
sequenc
encod
adjuv
also
ad
enhanc
vaccin
potenc
hepat
c
viru
vaccin
transgen
encod
total
five
protein
singl
promot
report
immun
chimpanze
furthermor
data
suggest
select
immunogen
antigen
incorpor
construct
well
optim
codon
usag
may
crucial
vaccin
success
polyadenyl
sequenc
essenti
aspect
gene
express
play
import
role
mrna
stabil
translat
vector
contain
bovin
growth
hormon
polyadenyl
signal
studi
reveal
latter
twotim
effici
therefor
commonli
use
current
vaccin
classifi
five
type
liveattenu
inactiv
microorgan
subunit
vaccin
subunit
polysaccharid
protein
conjug
toxoid
genet
base
attenu
vaccin
avirul
organ
typic
due
cultur
passag
advers
condit
pathogen
weaken
purpos
human
vaccin
multipl
way
repeat
serial
passag
lessen
organ
virul
although
weaken
pathogen
still
infect
multipli
human
host
cell
provid
continu
antigen
stimul
elicit
cellular
humor
immun
similar
elicit
origin
pathogen
bacillu
bcg
sabin
measl
mump
rubella
vaccin
best
exampl
vaccin
platform
howev
everi
benefit
lie
risk
case
risk
revers
virul
strain
reason
administ
immunocompromis
patient
kill
vaccin
hand
consist
inactiv
virul
pathogen
chemic
risk
mutat
revers
platform
howev
induc
humor
immun
respons
multipl
booster
requir
protect
exampl
inactiv
vaccin
common
use
today
typhoid
salk
poliomyel
vaccin
subunit
vaccin
purifi
antigen
protein
pathogen
flagella
capsul
surfac
protein
although
produc
larg
scale
poorli
immunogen
induc
humor
immun
respons
requir
booster
vaccin
everi
year
subunit
vaccin
also
use
gener
humor
immun
respons
polysaccharid
capsul
bacteria
case
polysaccharid
antigen
conjug
carrier
protein
increas
immunogen
exampl
platform
could
includ
haemophilu
influenza
b
hib
bordetella
pertussi
vaccin
lastli
toxoid
vaccin
base
inactiv
bacteri
toxin
success
induc
neutral
antibodi
virul
factor
major
disadvantag
need
booster
develop
advers
reaction
possibl
manufactur
issu
detoxif
process
wide
use
vaccin
clostridium
tetani
toxin
one
exampl
although
mechan
immun
induct
genet
vaccin
confer
protect
still
remain
unclear
slow
rise
immun
respons
follow
dna
immun
suggest
follow
complex
pathway
mimic
natur
viral
infect
howev
believ
dna
plasmid
administ
skin
subcutaneum
vein
nasal
caviti
muscl
plasmid
vector
enter
cell
transloc
nucleu
transcript
immunogen
initi
use
host
cellular
machineri
two
major
type
cell
becom
transfect
method
myocyt
antigenpres
cell
apc
studi
fish
show
cell
take
dna
hepatocyt
keratinocyt
follow
transfect
host
cell
replic
machineri
translat
transgen
protein
peptid
subsequ
present
mhci
immun
system
addit
antigen
protein
secret
around
surround
tissu
either
activ
secret
protein
releas
follow
apoptosi
transfect
cell
shed
antigen
protein
engulf
present
apc
mhci
mhcii
antigenload
apc
migrat
correspond
drain
lymph
node
activ
naiv
cell
costimulatori
signal
help
trigger
immun
respons
recruit
cell
lymph
node
cell
secret
cytokin
shed
antigen
activ
b
cell
induc
antibodi
product
initi
wave
tand
bcell
activ
small
cell
migrat
back
vaccinetransfect
tissu
undergo
restimul
point
cell
lyse
transfect
myocyt
present
antigen
peptid
mhci
molecul
caus
releas
antigen
furthermor
cell
activ
immatur
dendrit
cell
dc
later
drain
lymph
node
take
whole
new
cohort
b
cell
repeat
cycl
activ
therefor
humor
cellular
immun
respons
prime
next
challeng
summari
vaccin
platform
mechan
action
provid
figur
genet
vaccin
numer
advantag
tradit
vaccin
term
safeti
eas
manufactur
stabil
possibl
best
current
vaccin
platform
induc
humor
cellular
immun
respons
use
liveattenu
pathogen
howev
also
pose
import
safeti
concern
risk
revers
pathogen
virul
form
dna
vaccin
also
induc
longlast
cellular
humor
immun
respons
revert
virul
therefor
rais
fewer
safeti
concern
addit
clinic
trial
dna
vaccin
shown
fewer
incid
system
advers
effect
red
transient
pain
swell
fever
headach
also
report
pose
risk
integr
genom
earlier
concern
techniqu
develop
furthermor
dna
vaccin
advantag
use
therapeut
sinc
unabl
induc
antivector
immun
case
recombin
vaccin
theoret
unlimit
boost
potenti
could
especi
use
develop
field
cancer
vaccin
reli
repeat
boost
tcell
respons
tumor
antigen
import
factor
preserv
potenc
vaccin
maintain
proper
storag
condit
ensur
stabil
content
cold
storag
must
ensur
surviv
live
vaccin
preserv
origin
structur
subunit
vaccin
order
remain
antigen
effect
difficult
continu
problem
tropic
countri
endem
area
advantag
dna
vaccin
highli
stabl
requir
refriger
therefor
dna
vaccin
may
practic
use
develop
nation
cold
chain
like
compromis
addit
current
vaccin
complic
biolog
structur
make
modif
difficult
accomplish
exampl
take
approxim
month
entir
influenza
viru
product
process
complet
mean
compani
predict
almost
year
advanc
strain
includ
vaccin
sometim
predict
incorrect
lead
higher
number
influenza
infect
expect
particular
year
owe
simpl
structur
dna
vaccin
modif
transgen
made
short
period
time
reflect
specif
pathogen
strain
sinc
dna
vaccin
also
easili
replic
amplifi
bacteria
permit
fast
cheap
largescal
product
within
short
time
despit
obviou
advantag
lack
potenc
firstgener
dna
vaccin
question
due
lacklust
result
human
compar
mice
thu
investig
dilig
work
new
way
improv
potenc
techniqu
develop
novel
adjuv
codon
optim
scheme
innov
method
deliveri
make
suitabl
immunogen
human
vaccin
codon
optimizationcodon
optim
involv
specif
alter
gene
sequenc
maxim
gene
express
foreign
host
cell
base
upon
commonli
avail
level
trna
cell
way
optim
codon
util
tdna
abund
cell
result
higher
rate
protein
translat
describ
sever
author
furthermor
mrna
optim
also
essenti
higher
gene
express
larg
number
cg
sequenc
mrna
inhibit
protein
translat
increas
format
secondari
structur
presenc
cryptic
splice
site
abl
caus
anomal
gene
express
exist
cisact
element
rna
molecul
dictat
specif
transport
translat
pattern
local
mrna
graf
et
al
obtain
signific
immun
respons
mice
immun
optim
synthet
gene
wildtyp
control
owe
increas
mrna
stabil
codon
mrna
optim
improv
product
complex
macromolecul
led
higher
yield
antibodi
untransl
regionsregul
gene
express
element
locat
encod
gene
critic
regul
vaccin
gene
express
modif
kozak
consensu
sequenc
insert
upstream
gene
well
addit
doubl
stop
codon
guarante
increas
vitro
express
mrna
stabil
cytosinephosphateguanineunmethyl
cytosinephosphateguanin
cpg
motif
term
gacgtt
mice
gtcgtt
human
respons
activ
tolllik
receptor
tlr
dimer
thu
play
key
role
innat
acquir
immun
stimul
b
lymphocyt
convent
plasmocytoid
dc
macrophag
natur
killer
nk
cell
nkt
cell
receptor
discrimin
host
foreign
dna
base
sequenc
howev
larg
absent
human
cell
adjuv
properti
safeti
vaccin
platform
infecti
diseas
differ
anim
model
clearli
review
klinman
et
al
cpg
use
dna
vaccin
platform
sever
occas
name
inclus
cpg
hepat
b
vaccin
prior
inocul
hivseroposit
patient
capabl
enhanc
antigen
product
thelper
cell
respons
vaccin
antigen
also
uncertainti
regard
influenc
noncpg
element
bind
tendenc
current
studi
nextgener
dna
vaccin
requir
appropri
deliveri
technolog
chosen
method
rout
administr
play
key
role
magnitud
qualiti
trigger
immun
respons
therefor
determin
way
dna
vaccin
prime
immun
respons
critic
engin
type
immun
respons
induc
mean
dermal
deliveri
first
elicit
humor
respons
product
iga
igg
intramuscular
inject
prime
cellular
respons
activ
ctl
product
igg
antibodi
tradit
skin
popular
approach
vaccin
owe
access
size
cell
popul
compris
langerhan
cell
apc
migrat
lymphocyt
cell
amid
cutan
techniqu
follow
mention
subcutan
intraderm
inject
although
target
skin
fibroblast
keratinocyt
techniqu
requir
refin
dna
tattoo
modern
intraderm
version
cross
socal
simian
barrier
obtain
encourag
result
murin
nonhuman
primat
case
immun
topic
dermavir
transfect
langerhan
cell
via
dermal
patch
consist
nanoparticl
carri
antigenencod
plasmid
dna
paint
dna
consist
strip
layer
skin
order
acheiv
success
transfect
okuda
et
al
report
use
fast
adhes
glue
purpos
suggest
multipl
administr
adhes
tape
combin
sodium
dodecyl
sulphat
urea
cream
clinic
applic
assist
vesicular
system
involv
applic
vaccin
intact
skin
facilit
carrier
liposom
niosom
ethosom
transfersom
particlemedi
epiderm
deliveri
gene
gun
langerhan
cell
keratinocyt
becom
directli
transfect
bombard
gold
particl
coat
dna
needlefre
devic
sever
advantag
make
capabl
selfadministr
use
current
clinic
trial
specifi
requir
less
dna
coat
particl
stabl
need
cold
chain
thu
avoid
needlestick
injuri
dispos
sharp
issu
howev
intramuscular
inject
proven
practic
also
effect
transfect
myocyt
infiltr
apc
elicit
longlast
immun
earli
studi
prefer
special
rout
specif
purpos
like
vagin
mucosa
intranas
oral
administr
addit
chemic
physic
augment
transfect
wide
studi
prima
donna
technolog
innov
electropor
electropermeabil
method
applic
short
high
voltag
puls
millisecond
durat
tissu
disrupt
cell
membran
gener
pore
persist
hour
allow
entri
macromolecul
drug
peptid
nake
dna
vaccin
cytoplasm
sum
although
major
mechan
electropor
enhanc
vaccin
potenc
increas
gene
transfect
also
increas
distribut
plasmid
dna
throughout
tissu
furthermor
gener
local
danger
signal
due
product
endogen
cytokin
consequ
recruit
immun
cell
site
administr
involv
tcell
migrat
mechan
easi
pass
thread
eye
needl
certain
paramet
regard
puls
length
voltag
number
puls
equip
formul
optim
obtain
superior
effect
nevertheless
doubt
demonstr
potenti
sever
preclin
clinic
studi
includ
sarscov
hepat
c
viru
chikungunya
viru
author
comment
disadvantag
electropor
other
also
explain
complex
electropor
machin
design
may
mean
receiv
less
attent
human
applic
instead
believ
field
worth
pursu
search
advanc
strategi
develop
patch
contain
electrod
due
promis
outcom
anoth
electr
driven
method
wide
studi
pharmacolog
field
iontophoresi
involv
low
electricaldriven
forc
promot
movement
ion
stratum
corneum
without
chang
natur
skin
barrier
iontophoresi
use
optim
intraderm
deliveri
dna
vaccin
therefor
optim
transfect
furthermor
investig
privat
sector
led
number
novel
technolog
may
applic
vaccin
sonophoresi
chemic
permeat
enhanc
microneedl
six
differ
physic
method
gene
transfer
includ
ultrasound
magnet
electr
mediat
one
analyz
term
mechan
advantag
disadvantag
villemejan
mir
conclud
choic
one
depend
propos
therapeut
applic
use
deliv
gene
tissu
preferenti
target
limit
among
techniqu
donnelli
et
al
explain
dna
vaccin
formul
phagocytos
microparticl
like
polylactidecoglycolid
broadli
use
drug
deliveri
exclus
target
apc
multipl
vesicular
system
carrier
liposom
niosom
ethosom
transfersom
also
extens
studi
latter
use
option
furthermor
intracellular
bacteria
costeffect
deliveri
method
liveattenu
bacteri
deliveri
vaccin
proven
efficaci
infecti
diseas
cancer
exampl
includ
salmonella
typhi
listeria
monocytogen
shigella
flexneri
yersinia
enterocolitica
invas
e
coli
final
nanotechnolog
complex
dna
current
explor
facilit
receptormedi
vaccin
intern
technolog
present
appli
drug
deliveri
explor
deliveri
diagnost
agent
gene
therapi
case
dna
vaccin
method
pursu
goal
enhanc
dna
transfect
increas
potenc
dna
vaccin
accord
mani
laboratori
coinject
immunomodulatori
plasmid
encod
cytokin
chemokin
costimulatori
molecul
promis
strategi
improv
efficaci
dna
vaccin
aim
expand
apc
pool
enhanc
potenc
adjuv
without
advers
effect
administ
purifi
cytokin
protein
howev
among
cytokin
plenti
interleukin
il
interferon
ifn
colonystimul
factor
tumor
necrosi
factor
tnf
coadminist
engin
vaccin
use
differ
aspect
immun
respons
thu
provid
flexibl
modul
type
immun
respons
desir
method
also
notic
increas
efficaci
primeboost
strategi
help
compens
weak
outcom
due
antivector
immun
recombin
vaccin
exampl
pretreat
plasmid
encod
granulocytemacrophag
colonystimul
factor
gmcsf
increas
recruit
dc
immun
site
expand
profession
apc
lymph
node
laddi
weiner
state
lack
clinic
use
accord
clinic
trial
result
contrast
recent
work
phase
ii
clinic
trial
involv
previou
applic
gmcsf
dna
follow
multipeptid
vaccin
melanoma
patient
abl
elicit
polyfunct
tcell
respons
data
accord
found
mice
murin
gmcsf
amplifi
hiv
antigenspecif
tcell
prolifer
increas
proport
antigenspecif
polyfunct
memori
cell
techniqu
enhanc
magnitud
respons
also
qualiti
plasmid
dna
vaccin
combin
order
increas
humor
cellular
respons
latest
anim
model
pathogen
mycobacterium
tuberculosi
infecti
bronchiti
viru
human
papillomaviru
barouch
et
al
also
report
fusion
ig
protein
even
effici
augment
cellular
respons
increas
halflif
avid
year
later
publish
effect
like
due
enhanc
initi
prime
memori
lymphocyt
due
chronic
cytokin
express
furthermor
adjuv
significantli
increas
antigenspecif
respons
maintain
lt
memori
cell
recent
implic
vaccin
develop
test
rhesu
macaqu
show
alon
along
elev
cellmedi
humor
immun
respons
brief
even
better
result
could
obtain
combin
electropor
similar
play
import
role
respons
due
induct
synthesi
nk
cell
wei
et
al
select
adjuv
vaccin
schistosoma
japonicum
lead
notabl
antibodi
respons
well
splenocyt
prolif
respons
furthermor
rant
identifi
enhanc
antigenspecif
tcell
respons
herp
simplex
viru
hsv
vaccin
result
better
surviv
rate
less
sever
herpet
lesion
final
found
effect
immunocompromis
mice
malaria
influenza
immun
given
dc
play
central
role
prime
immun
respons
upregul
activ
combin
plasmid
encod
chemokin
macrophag
inflammatori
dcspecif
growth
factor
fmslike
tyrosin
kinas
ligand
promis
approach
gener
expans
matur
chemoattract
synerg
work
inject
site
use
show
dramat
augment
antibodi
product
proven
potent
activ
import
howev
understand
synerg
activ
molecul
gmcsf
administ
alon
macrophag
recruit
immun
site
respons
trigger
case
administr
dc
recruit
induc
tcell
respons
interestingli
plasmid
coadminist
respons
observ
suggest
addit
effect
addit
adjuv
altern
may
modif
intraand
extracellular
traffick
amplifi
respons
target
antigen
degrad
ubiquitin
ub
proteosom
pathway
allow
effici
process
present
mhc
class
pathway
method
could
also
use
amplifi
respons
lysosom
endosom
target
could
gener
higher
antibodi
product
plasmid
encod
cytotox
lymphocyteassoci
antigen
lselectin
furthermor
immunogen
plasmid
dna
may
due
part
product
type
ifn
follow
cellular
detect
intracellular
dsdna
signal
molecul
includ
sting
complex
traffic
endosom
compart
associ
exocyst
compon
includ
thu
data
regard
use
plasmidbas
molecular
adjuv
promis
prolif
data
suggest
techniqu
could
help
augment
previous
weak
respons
confer
firstgener
dna
vaccin
howev
still
lot
learn
regard
complex
behavior
specif
adjuv
use
combin
nextgener
dna
vaccin
instead
improv
vaccin
immunogen
increas
number
dose
research
suggest
use
mix
vaccin
prime
first
formul
boost
differ
one
remark
plotkin
heterolog
primeboost
strategi
way
increas
dna
vaccin
potenc
particularli
antibodi
product
either
employ
nake
dna
follow
gene
carri
vector
two
differ
vector
carri
gene
howev
remark
vector
recombin
vaccin
induc
immun
use
virus
popul
natur
expos
ineffect
similar
case
seen
boost
viral
recombin
like
vaccinia
viru
mva
adenoviru
prime
dna
vaccin
may
counterbal
interfer
although
studi
develop
preclin
clinic
stage
human
veterinari
applic
fix
primeboost
regimen
still
avail
recent
public
veterinari
field
demonstr
combin
gene
gunmedi
nake
dna
vector
prime
mva
booster
mice
attract
line
attack
porcin
circoviru
type
vaccin
scheme
highli
pathogen
avian
influenza
ashp
viru
reveal
prime
fowlpoxvector
vaccin
follow
boost
inactiv
vaccin
stimul
broader
protect
two
administr
fowlpox
recombin
asia
case
human
diseas
encourag
result
mice
regard
jev
point
pdnatep
primerecombin
protein
rep
provok
develop
strong
humor
cellular
immun
respons
moreov
eager
develop
univers
influenza
vaccin
lo
et
al
report
choos
dna
primerad
boost
seem
attract
altern
provid
robust
heterosubtyp
immun
vaccin
coldadapt
viru
recent
primeboost
regimen
appli
larg
number
vaccin
includ
hiv
avian
influenza
viru
malaria
anthrax
tb
certain
nosocomi
infect
inform
demonstr
incorpor
primeboost
regimen
vaccin
platform
may
yield
better
outcom
new
vaccin
need
fight
antibiot
resist
better
control
bacteri
diseas
total
nine
bacteri
pathogen
target
licens
vaccin
accord
record
fda
none
base
gene
vaccin
tabl
mortal
morbid
rate
still
high
regardless
usag
current
bacteri
vaccin
suggest
novel
techniqu
requir
despit
dna
vaccin
mode
action
prototyp
tumor
cell
infecti
autoimmun
diseas
although
clear
genet
vaccin
sever
advantag
type
vaccin
applic
bacteri
infect
scarc
document
report
differ
way
induc
immun
respons
bacteria
describ
sinc
emerg
technolog
studi
use
fish
target
vibrio
anguillarum
edwardsiella
tarda
show
could
protect
dna
vaccin
virus
provok
specif
nonspecif
immun
depend
pathogen
bacteri
infect
host
typic
mount
type
respons
requir
erad
intracellular
bacteria
combat
predominantli
cellular
respons
extracellular
bacteria
antibodi
product
nevertheless
antibodi
indispens
control
bacteri
infect
howev
complex
bacteria
gener
requir
develop
antibodi
differ
structur
protein
toxin
capsul
sugar
understand
relev
microbi
antigen
epitop
elicit
effect
respons
key
progress
dna
vaccin
develop
complet
dna
sequenc
bacteria
decod
research
select
appropri
antigen
design
specif
construct
special
concern
regard
express
bacteri
protein
eukaryot
cell
particularli
host
cell
synthet
machineri
express
bacteri
antigen
result
difficulti
fold
transport
posttransl
modif
lead
unwant
effect
anoth
challeng
design
vaccin
carbohydr
antigen
classifi
thymusindepend
antigen
elicit
respons
poorli
immunogen
young
children
igm
domin
lack
isotyp
switch
memori
respons
anoth
major
problem
capsular
monosaccharid
link
mani
differ
way
form
epitop
lead
great
serolog
variabl
sum
capsular
polysaccharid
certain
pathogen
structur
similar
host
endogen
carbohydr
lead
possibl
autoimmun
respons
immun
howev
develop
peptid
mimic
antigen
open
possibl
induc
tlymphocytedepend
polysaccharid
immun
mechan
mimicri
complet
understood
peptid
identifi
either
phage
display
librari
antiidiotyp
antibodi
also
publish
peptid
immun
respons
predomin
igg
particularli
import
encapsul
organ
abil
fix
complement
opson
first
report
dna
vaccin
achiev
tdepend
respons
polysaccharid
antigen
perform
kieberemmon
et
al
balbc
mice
immun
use
plasmid
encod
design
peptid
mimotop
neolactoseri
antigen
lewi
induc
antibodi
respons
igg
isotyp
result
show
use
antiidiotyp
immunoglobulin
act
surrog
imag
polysaccharid
neisseria
meningitidi
could
protect
mice
lethal
exposur
pathogen
construct
consist
multiepitop
dna
vaccin
encod
peptid
mimic
meningococc
serogroup
c
capsular
polysaccharid
univers
tcell
helper
epitop
secretari
leader
sequenc
although
seem
proven
altern
sever
problem
need
solv
found
poor
chemic
stabil
thu
lower
antigen
addit
smaller
peptid
degrad
easili
result
ineffect
respons
also
technic
issu
regard
product
antiidiotyp
monoclon
antibodi
bacteri
pathogen
still
respons
increas
mortal
rate
worldwid
avail
vaccin
limit
small
number
bacteri
organ
confer
full
protect
dna
vaccin
technolog
appli
differ
type
bacteria
import
role
human
infect
exampl
mention
previous
tabl
helicobact
pylorihelicobact
pylori
gramneg
microaerophil
spirochet
infect
half
world
popul
colon
antral
region
stomach
capabl
surviv
stomach
hostil
environ
due
virul
factor
classifi
class
carcinogen
mean
proven
carcinogen
human
high
preval
worldwid
h
pylori
infect
role
pathogenesi
gastriti
peptic
ulcer
maltoma
adenocarcinoma
make
import
target
dna
vaccin
although
antibiot
therapi
treatment
choic
resist
strain
recent
identifi
studi
demonstr
efficaci
plasmid
encod
neutrophil
activ
protein
ureas
b
protein
elicit
good
immunogen
respons
anim
model
shown
ureas
b
vaccin
could
induc
upregul
lower
bacteri
load
stomach
other
conclud
immun
respons
heatshock
protein
effect
also
decreas
level
gastric
mucos
inflamm
bacillu
anthracisbacillu
anthraci
gramposit
rodshap
bacteria
form
spore
virul
factor
consist
two
toxin
result
combin
protect
antigen
pa
either
lethal
factor
edema
factor
caus
diseas
contact
inhal
ingest
spore
public
health
prioriti
develop
vaccin
biothreat
anthrax
effici
cheap
stabl
easi
transport
vaccin
platform
dna
vaccin
need
biodefens
purpos
current
vaccin
anthrax
ava
base
bacteri
supernat
absorb
tabl
proven
reactogen
complic
schedul
follow
contrari
dna
vaccin
present
disadvantag
induc
antipa
immun
larg
associ
anthrax
protect
first
attempt
induc
protect
lethal
toxin
challeng
perform
gu
et
al
obtain
neutral
antibodi
addit
cytokinesecret
cell
correspond
product
igg
igg
recent
assay
shown
vaccin
optim
dna
encod
anthrax
protect
antigen
follow
electropor
induc
rapid
neutral
antipa
igg
respons
mice
rat
rabbit
tuberculosi
mycobacterium
tuberculosi
aerob
intracellular
bacterium
respons
approxim
million
death
year
worldwid
undoubtedli
one
major
pathogen
research
eager
target
increas
number
case
seen
year
lower
efficaci
bcg
vaccin
control
pulmonari
infect
reason
novel
vaccin
altern
test
multidrugresist
strain
coinfect
greatest
challeng
novel
vaccin
techniqu
nucleic
acid
vaccin
good
candid
prophylaxi
intracellular
pathogen
like
mycobacterium
due
respons
mediat
induc
tb
dna
vaccin
therapeut
protect
purpos
proven
restor
balanc
result
signific
reduct
patholog
anim
differ
antigen
given
alon
recombin
dna
vaccin
investig
date
vaccin
alon
test
clinic
trial
proven
effect
mycobacterium
bcg
famili
far
studi
encod
antigen
tb
vaccin
studi
shown
induc
robust
immun
respons
elev
effect
target
antigen
fbphtpx
among
other
vaccin
schedul
consist
prime
bcg
boost
specif
dna
vaccin
order
achiev
superior
respons
compar
bcg
alon
possibl
way
improv
efficaci
give
vaccin
pool
combin
antigen
correct
adjuv
like
deliv
construct
cation
lipid
formul
correct
combin
deliveri
method
rout
administr
describ
rosada
et
alwho
design
tb
vaccin
consist
singl
intranas
dose
complex
cation
liposom
construct
effect
elicit
cellular
immun
respons
strong
induc
four
intramuscular
dose
nake
dna
even
reduc
number
bacilli
lung
differ
challeng
model
requir
test
efficaci
safeti
plasmidbas
vaccin
mice
guinea
pig
rabbit
frequent
use
anim
model
tb
studi
either
intraven
pulmonari
infect
histopatholog
analysi
surviv
curv
bacterialload
count
necessari
best
nonhuman
primat
model
human
tb
cynomolgu
monkey
also
known
macaca
fasciculari
first
success
tb
vaccin
monkey
model
report
okada
combin
heatshock
protein
obtain
better
efficaci
chest
xray
find
immun
respons
bcg
control
infecti
diseas
like
tb
high
prioriti
work
requir
obtain
ideal
tb
vaccin
studi
provid
evid
begin
promis
date
sever
preclin
clinic
studi
dna
vaccin
remark
past
year
four
dna
vaccin
larger
anim
licens
use
veterinari
field
precis
two
target
infecti
diseas
like
west
nile
viru
hors
aquat
rhabdoviru
call
infecti
hematopoiet
necrosi
salmon
one
cancer
vaccin
melanoma
dog
last
one
therapeut
purpos
swine
plasmidmediatedreleas
growth
hormon
supplement
deliv
specif
vaccin
demonstr
enhanc
protect
mycoplasma
hyopneumonia
although
anim
diseas
model
complet
similar
human
past
success
dna
vaccin
reveal
promis
futur
toward
use
technolog
target
human
diseas
benefici
renov
improv
perform
techniqu
merit
test
clinic
trial
larg
number
current
oper
mainli
test
safeti
efficaci
effici
vaccin
target
virus
hepat
b
viru
malaria
cancer
cell
like
melanoma
bacteri
vaccin
test
less
trial
antibiot
seem
reason
solut
fact
chang
past
year
emerg
resist
strain
tb
typhoid
fever
anthrax
dna
vaccin
popular
candid
enter
clinic
trial
major
studi
perform
use
recombin
vaccin
techniqu
induc
antivector
immun
gene
therapybas
vaccin
bacteri
pathogen
proven
effect
howev
research
accumul
data
platform
upcom
clinic
trial
expert
state
base
clinic
result
combin
vaccin
strategi
primeboost
approach
futur
immun
pathogen
like
tuberculosi
rather
singl
vaccin
candid
current
licens
vaccin
human
use
limit
term
manufactur
storag
potenc
safeti
dna
vaccin
novel
broadli
studi
vaccin
strategi
offer
complet
differ
system
trigger
longlast
cellular
humor
respons
wide
varieti
pathogen
without
limit
mention
beauti
dna
vaccin
lie
simpl
concept
versatil
accomplish
immun
infecti
diseas
well
cancer
although
dna
vaccin
target
bacteri
pathogen
test
encourag
result
obtain
wider
rang
organ
target
vaccin
use
fight
antibioticresist
strain
trigger
immun
respons
children
year
age
facilit
control
epidem
new
approach
studi
creat
vaccin
type
bacteria
virul
factor
polysaccharid
capsul
toxin
opinion
worthi
field
pursu
potenti
advantag
public
health
revolutionari
technolog
face
challeng
enhanc
potenc
stand
nextgener
vaccin
platform
although
dna
vaccin
alreadi
test
clinic
trial
new
method
augment
immunogen
codon
optim
adjuv
deliveri
method
includ
electropor
nanoparticl
evalu
preclin
studi
reveal
evid
potenti
platform
vitro
vivo
model
year
sinc
field
dna
vaccin
emerg
biomed
limelight
period
field
difficult
time
recent
howev
sever
import
technic
improv
design
formul
synthesi
deliveri
list
articl
contribut
recent
resurg
interest
start
exhibit
improv
perform
larger
anim
clinic
concept
dna
vaccin
studi
wide
array
pathogen
tumor
antigen
preclin
clinic
stage
clear
measur
progress
howev
bacteri
pathogen
target
dna
vaccin
although
antibiot
convent
vaccin
use
past
emerg
resist
strain
bacteri
pathogen
becom
major
roadblock
clinic
clinic
trial
number
countri
convent
vaccin
like
bcg
tb
vaccin
exampl
reveal
heterogen
degre
protect
rang
similar
disappoint
seen
case
sever
bacteri
pathogen
recent
paradigm
protect
gener
dna
vaccin
hitherto
reli
mainli
gener
cellular
immun
shift
incorpor
contribut
humor
compon
immun
protect
pathogen
accordingli
vaccin
approach
renew
interest
bacteri
pathogen
specif
dna
vaccin
develop
mycobacterium
speci
includ
mycobacterium
lepra
mycobacterium
avium
mycobacterium
ulceran
among
target
avail
suitabl
murin
model
test
vaccin
efficaci
effort
translat
studi
human
next
year
test
crucial
gener
clinic
success
base
immun
potenc
improv
vaccin
design
includ
better
formul
better
deliveri
techniqu
incorpor
adjuv
support
joint
effort
research
organ
industri
regulatori
author
could
final
pave
way
toward
success
dna
vaccin
bacteri
pathogen
distant
futur
dna
vaccin
involv
intramuscular
subcutan
inject
dna
plasmid
contain
transgen
encod
sequenc
target
protein
pathogen
control
eukaryot
promot
induc
longlast
humor
cellular
immun
respons
construct
consist
plasmid
backbon
transcript
unit
contain
promot
insert
gene
encod
antigen
interest
follow
transcript
terminationpolyadenyl
sequenc
multipl
method
exist
enhanc
immunogen
dna
vaccin
everi
step
way
codon
optim
molecular
adjuv
electropor
four
dna
vaccin
larger
anim
licens
veterinari
use
current
clinic
trial
also
shown
safeti
effici
efficaci
predict
combin
vaccin
strategi
primeboost
approach
futur
immun
pathogen
like
mycobacterium
tuberculosi
dna
vaccin
major
advantag
exist
vaccin
platform
make
suitabl
option
control
bacteri
infecti
diseas
era
antibiot
resist
dna
vaccin
target
bacteri
pathogen
helicobact
pylori
tuberculosi
bacillu
anthraci
test
encourag
result
develop
peptid
mimic
carbohydr
antigen
open
possibl
induc
tlymphocytedepend
polysaccharid
immun
inject
dna
vaccin
plasmid
dna
vaccin
vector
design
antitt
antibodi
bacillu
anthraci
protein
adsorb
intramuscular
antipa
antibodi
bordetella
pertussi
acellular
intramuscular
antifha
prn
pt
bpt
antibodi
corynebacterium
diphteria
toxoid
adsorb
intramuscular
antidt
antibodi
extracellular
neisseria
meningitidi
serogroup
c
polysaccharideprotein
conjug
subcutan
anticapsular
polysaccharid
antibodi
haemophilu
influenza
type
b
polysaccharideprotein
conjug
intramuscular
antiprp
antibodi
streptococcu
pneumonia
